166 related articles for article (PubMed ID: 16626170)
21. Hepatic sinusoidal obstruction after gemtuzumab ozogamicin (Mylotarg) therapy.
Rajvanshi P; Shulman HM; Sievers EL; McDonald GB
Blood; 2002 Apr; 99(7):2310-4. PubMed ID: 11895761
[TBL] [Abstract][Full Text] [Related]
22. A Phase I Study of Reduced-Intensity Conditioning and Allogeneic Stem Cell Transplantation Followed by Dose Escalation of Targeted Consolidation Immunotherapy with Gemtuzumab Ozogamicin in Children and Adolescents with CD33+ Acute Myeloid Leukemia.
Zahler S; Bhatia M; Ricci A; Roy S; Morris E; Harrison L; van de Ven C; Fabricatore S; Wolownik K; Cooney-Qualter E; Baxter-Lowe LA; Luisi P; Militano O; Kletzel M; Cairo MS
Biol Blood Marrow Transplant; 2016 Apr; 22(4):698-704. PubMed ID: 26785332
[TBL] [Abstract][Full Text] [Related]
23. Gemtuzumab-ozogamicin in combination with fludarabine, cytarabine, idarubicin (FLAI-GO) as induction therapy in CD33-positive AML patients younger than 65 years.
Candoni A; Martinelli G; Toffoletti E; Chiarvesio A; Tiribelli M; Malagola M; Piccaluga PP; Michelutti A; Simeone E; Damiani D; Russo D; Fanin R
Leuk Res; 2008 Dec; 32(12):1800-8. PubMed ID: 18621416
[TBL] [Abstract][Full Text] [Related]
24. Efficacy of fractionated gemtuzumab ozogamicin combined with cytarabine in advanced childhood myeloid leukaemia.
Brethon B; Yakouben K; Oudot C; Boutard P; Bruno B; Jérome C; Nelken B; de Lumley L; Bertrand Y; Dalle JH; Chevret S; Leblanc T; Baruchel A
Br J Haematol; 2008 Nov; 143(4):541-7. PubMed ID: 18759760
[TBL] [Abstract][Full Text] [Related]
25. High CD33-antigen loads in peripheral blood limit the efficacy of gemtuzumab ozogamicin (Mylotarg) treatment in acute myeloid leukemia patients.
van der Velden VH; Boeckx N; Jedema I; te Marvelde JG; Hoogeveen PG; Boogaerts M; van Dongen JJ
Leukemia; 2004 May; 18(5):983-8. PubMed ID: 15029214
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse.
Sievers EL; Larson RA; Stadtmauer EA; Estey E; Löwenberg B; Dombret H; Karanes C; Theobald M; Bennett JM; Sherman ML; Berger MS; Eten CB; Loken MR; van Dongen JJ; Bernstein ID; Appelbaum FR;
J Clin Oncol; 2001 Jul; 19(13):3244-54. PubMed ID: 11432892
[TBL] [Abstract][Full Text] [Related]
27. Dose-related efficacy and toxicity of gemtuzumab ozogamicin in pediatric acute myeloid leukemia.
Parigger J; Zwaan CM; Reinhardt D; Kaspers GJ
Expert Rev Anticancer Ther; 2016; 16(2):137-46. PubMed ID: 26646091
[TBL] [Abstract][Full Text] [Related]
28. Salvage treatment for children with refractory first or second relapse of acute myeloid leukaemia with gemtuzumab ozogamicin: results of a phase II study.
Zwaan CM; Reinhardt D; Zimmerman M; Hasle H; Stary J; Stark B; Dworzak M; Creutzig U; Kaspers GJ;
Br J Haematol; 2010 Mar; 148(5):768-76. PubMed ID: 19995399
[TBL] [Abstract][Full Text] [Related]
29. Gemtuzumab ozogamicin in acute myeloid leukemia.
Godwin CD; Gale RP; Walter RB
Leukemia; 2017 Sep; 31(9):1855-1868. PubMed ID: 28607471
[TBL] [Abstract][Full Text] [Related]
30. Molecular remission of Philadelphia/bcr-abl-positive acute myeloid leukaemia after treatment with anti-CD33 calicheamicin conjugate (gemtuzumab ozogamicin, CMA-676).
de Vetten MP; Jansen JH; van der Reijden BA; Berger MS; Zijlmans JM; Löwenberg B
Br J Haematol; 2000 Oct; 111(1):277-9. PubMed ID: 11091212
[TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetics of gemtuzumab ozogamicin as a single-agent treatment of pediatric patients with refractory or relapsed acute myeloid leukemia.
Buckwalter M; Dowell JA; Korth-Bradley J; Gorovits B; Mayer PR
J Clin Pharmacol; 2004 Aug; 44(8):873-80. PubMed ID: 15286091
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and tolerability of gemtuzumab ozogamicin (anti-CD33 monoclonal antibody, CMA-676, Mylotarg) in children with relapsed/refractory myeloid leukemia.
Brethon B; Auvrignon A; Galambrun C; Yakouben K; Leblanc T; Bertrand Y; Leverger G; Baruchel A
BMC Cancer; 2006 Jun; 6():172. PubMed ID: 16805911
[TBL] [Abstract][Full Text] [Related]
33. Population Pharmacokinetic Modeling of Gemtuzumab Ozogamicin in Adult Patients with Acute Myeloid Leukemia.
Hibma J; Knight B
Clin Pharmacokinet; 2019 Mar; 58(3):335-347. PubMed ID: 30062662
[TBL] [Abstract][Full Text] [Related]
34. CD33-directed therapy with gemtuzumab ozogamicin in acute myeloid leukemia: progress in understanding cytotoxicity and potential mechanisms of drug resistance.
Linenberger ML
Leukemia; 2005 Feb; 19(2):176-82. PubMed ID: 15592433
[TBL] [Abstract][Full Text] [Related]
35. Biomarkers of Gemtuzumab Ozogamicin Response for Acute Myeloid Leukemia Treatment.
Fenwarth L; Fournier E; Cheok M; Boyer T; Gonzales F; Castaigne S; Boissel N; Lambert J; Dombret H; Preudhomme C; Duployez N
Int J Mol Sci; 2020 Aug; 21(16):. PubMed ID: 32781546
[TBL] [Abstract][Full Text] [Related]
36. Gemtuzumab ozogamicin (Mylotarg) as single-agent treatment for frail patients 61 years of age and older with acute myeloid leukemia: final results of AML-15B, a phase 2 study of the European Organisation for Research and Treatment of Cancer and Gruppo Italiano Malattie Ematologiche dell'Adulto Leukemia Groups.
Amadori S; Suciu S; Stasi R; Willemze R; Mandelli F; Selleslag D; Denzlinger C; Muus P; Stauder R; Berneman Z; Pruijt J; Nobile F; Cassibba V; Marie JP; Beeldens F; Baila L; Vignetti M; de Witte T
Leukemia; 2005 Oct; 19(10):1768-73. PubMed ID: 16079891
[TBL] [Abstract][Full Text] [Related]
37. Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia.
Stasi R; Evangelista ML; Buccisano F; Venditti A; Amadori S
Cancer Treat Rev; 2008 Feb; 34(1):49-60. PubMed ID: 17942233
[TBL] [Abstract][Full Text] [Related]
38. Gemtuzumab Ozogamicin Monotherapy Is a Well-tolerated Palliative Chemotherapy Option in Pediatric Multiply Relapsed Acute Myeloid Leukemia: A Multicenter Case Series and Review of the Literature.
Blain S; Payette N; Bittencourt H; Johnston DL
J Pediatr Hematol Oncol; 2023 Nov; 45(8):436-444. PubMed ID: 37807192
[TBL] [Abstract][Full Text] [Related]
39. Prevention, recognition, and management of adverse events associated with gemtuzumab ozogamicin use in acute myeloid leukemia.
Cortes JE; de Lima M; Dombret H; Estey EH; Giralt SA; Montesinos P; Röllig C; Venditti A; Wang ES
J Hematol Oncol; 2020 Oct; 13(1):137. PubMed ID: 33059764
[TBL] [Abstract][Full Text] [Related]
40. Gemtuzumab Ozogamicin in Acute Myeloid Leukemia: Efficacy, Toxicity, and Resistance Mechanisms-A Systematic Review.
Collados-Ros A; Muro M; Legaz I
Biomedicines; 2024 Jan; 12(1):. PubMed ID: 38255313
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
